Multiple predicted protein targets inferred from analogous Zhilong formulations, not directly confirmed for Zhilong Tongluo Tablets

Zhilong Tongluo Tablets (ZLT) are a Traditional Chinese Medicine (TCM) formulation primarily utilized in the treatment of ischemic stroke, diabetic nephropathy, and related vascular conditions (PMID: 31212158, PMID: 28751815). The formulation typically consists of several components, including Hirudo (leech), Pheretima (earthworm), and various botanical extracts like Astragalus, which contribute to its multi-target pharmacological profile. Research into analogous Zhilong formulations suggests that the therapeutic efficacy may be driven by the modulation of proteins involved in thrombosis, inflammation, and vascular remodeling. Common predicted targets include Prostaglandin-Endoperoxide Synthase 2 (PTGS2), Vascular Endothelial Growth Factor A (VEGFA), and Interleukin-6 (IL-6) (PMID: 32451234). Despite these predictions, specific molecular targets for the ZLT preparation itself have not been definitively confirmed through direct biochemical or structural studies. Therefore, the pharmacological action is currently understood through the lens of network pharmacology rather than a single-target mechanism. This entry represents a placeholder for a complex network of interactions rather than a single, validated therapeutic protein.

Other names

Zhilong Tongluo predicted targetsZLT targets

The mechanism of action is characterized by a multi-component, multi-target approach where various bioactive compounds (such as hirudin from leeches) modulate signaling pathways related to inflammation, oxidative stress, and coagulation (PMID: 31212158).